Literature DB >> 18330899

MYH9-siRNA and MYH9 mutant alleles: expression in cultured cell lines and their effects upon cell structure and function.

Yan Li1, David R Friedmann, Anand N Mhatre, Anil K Lalwani.   

Abstract

MYH9 encodes a class II nonmuscle myosin heavy chain-A (NMHC-IIA), a widely expressed 1960 amino acid polypeptide, with translated molecular weight of 220 kDa. From studies of type II myosin in invertebrates and analogy with the skeletal and smooth muscle myosin II, NMHC-IIA is considered to be involved in diverse cellular functions, including cell shape, motility and division. The current study assessed the consequences of two separate, naturally occurring MYH9 dominant mutant alleles, MYH9(R702C) and MYH9(R705H) linked to syndromic and nonsyndromic hearing loss, respectively, upon diverse NMHC-IIA related functions in two separate cultured cell lines. MYH9-siRNA-induced inhibition of NMHC-IIA in HeLa cells or HEK293 cells resulted in alterations in their shape, actin cytoskeleton and adhesion properties. However, HeLa or HEK293 cells transfected with naturally occurring MYH9 mutant alleles, MYH9(R702C) or MYH9(R705H), as well as in vitro generated deletion derivatives, MYH9(DeltaN592) or MYH9(DeltaC570), were unaffected. The effects of MYH9-siRNA-induced suppression underline the critical role of NMHC-IIA in maintenance of cell shape and adhesion. However, the results also indicate that the NMHC-IIA mutants, R702C and R705H do not inactivate or suppress the endogenous wild type NMHC-IIA within the HeLa or HEK293 cell assay system. Copyright 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18330899     DOI: 10.1002/cm.20268

Source DB:  PubMed          Journal:  Cell Motil Cytoskeleton        ISSN: 0886-1544


  6 in total

1.  Cdk1-dependent mitotic enrichment of cortical myosin II promotes cell rounding against confinement.

Authors:  Subramanian P Ramanathan; Jonne Helenius; Martin P Stewart; Cedric J Cattin; Anthony A Hyman; Daniel J Muller
Journal:  Nat Cell Biol       Date:  2015-01-26       Impact factor: 28.824

2.  Plasma from a case of recurrent idiopathic FSGS perturbs non-muscle myosin IIA (MYH9 protein) in human podocytes.

Authors:  Sima Babayeva; Michelle Miller; Yulia Zilber; Reyhan El Kares; Chantale Bernard; Martin Bitzan; Paul Goodyer; Elena Torban
Journal:  Pediatr Nephrol       Date:  2011-03-06       Impact factor: 3.714

3.  MYH9 Promotes Growth and Metastasis via Activation of MAPK/AKT Signaling in Colorectal Cancer.

Authors:  Bin Wang; Xiaolong Qi; Jian Liu; Rui Zhou; Chuang Lin; Junjie Shangguan; Zhuoli Zhang; Liang Zhao; Guoxin Li
Journal:  J Cancer       Date:  2019-01-29       Impact factor: 4.207

4.  Angiotensin II-mediated MYH9 downregulation causes structural and functional podocyte injury in diabetic kidney disease.

Authors:  Jeong Suk Kang; Seung Joo Lee; Ji-Hye Lee; Ji-Hee Kim; Seung Seob Son; Seung-Kuy Cha; Eun Soo Lee; Choon Hee Chung; Eun Young Lee
Journal:  Sci Rep       Date:  2019-05-22       Impact factor: 4.379

5.  Clinicopathological significance of NMIIA overexpression in human gastric cancer.

Authors:  Dongning Liu; Lei Zhang; Zhiyong Shen; Fei Tan; Yanfeng Hu; Jiang Yu; Guoxin Li
Journal:  Int J Mol Sci       Date:  2012-11-19       Impact factor: 5.923

6.  Proteomics analysis of the non-muscle myosin heavy chain IIa-enriched actin-myosin complex reveals multiple functions within the podocyte.

Authors:  Thomas Hays; Avi Ma'ayan; Neil R Clark; Christopher M Tan; Avelino Teixeira; Angela Teixeira; Jae W Choi; Nora Burdis; Sung Yun Jung; Amol O Bajaj; Bert W O'Malley; John C He; Deborah P Hyink; Paul E Klotman
Journal:  PLoS One       Date:  2014-06-20       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.